Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Explore the Synergy of Combination TKI Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02129166
Recruitment Status : Withdrawn (PI resigned)
First Posted : May 2, 2014
Last Update Posted : October 6, 2014
Sponsor:
Information provided by (Responsible Party):
University of Florida

Brief Summary:
This research study is looking at how imatinib affects how dasatinib is absorbed and eliminated from the body. Both imatinib and dasatinib are in a class of medications called tyrosine kinase inhibitors (TKI) and they are used to treat certain types of leukemia (cancer that begins in the white blood cells). Both imatinib and dasatinib have been given safely in healthy volunteers. In this study investigators will evaluate the pharmacokinetics interaction between imatinib and dasatinib when they are co-administered. The hypothesis is that imatinib will increase the blood levels of dasatinib through inhibiting the drug metabolizing enzyme and efflux transporter that are involved in the dasatinib absorption and removal. This research will provide important new insight of combination TKI therapy in terms of transporter- and enzyme- mediated pharmacokinetic interactions. The research results will also help guide doctors in knowing how much of a tyrosine kinase inhibitor to give safely while reaching best effect in TKI combination therapy.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Dasatinib Drug: Dasatinib+Imatinib Phase 1

Detailed Description:

If the subjects qualify to take part in this research study, they will undergo the following procedures.

Subjects will be asked to abstain from alcoholic beverages (24 hours), grapefruit products, herbal supplements/teas, and over-the-counter medications (48 hours) prior to the study visits. There will be two study periods in this study. During each period all the subjects are outpatients and there will be no overnight stay. During each study period, the subjects will come to the University of Florida Clinical Research Center (UF CRC) three times: on Day -1, Day 1, and Day 2, respectively. Subjects will report to the UF CRC the day before Day 1 (i.e. Day -1) to have clinical lab test and urine pregnancy test (female only). Subjects will come to UF CRC at 6:30 a.m. on Day 1 and Day 2 of each study visit. During the morning of each study period (around 8:30 am) subjects will be randomly assigned to receive a single oral dose of dasatinib 20 mg either with or without a single oral dose of imatinib 400 mg administered one hour prior to dasatinib. After the first study visit, the subjects will return one to two weeks later for the second study visit, receiving the opposite treatment. The treatment order for the study visits will be assigned randomly. The end point measures for this study are plasma concentrations of dasatinib. A total of twelve (12) blood samples will be collected for a total amount of 84 ml (about 3 ounces or about 6 tablespoonsful) for each subject during each study period.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Explore the Synergy of Combination TKI Therapy - A Pilot Study to Evaluate the Effect of Imatinib on Dasatinib Pharmacokinetics in Healthy Volunteers
Study Start Date : September 2014
Actual Primary Completion Date : October 2014
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Dasatinib
In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
Drug: Dasatinib
In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
Other Name: Sprycel

Active Comparator: Dasatinib+Imatinib

In this group, subjects will take imatinib prior to dasatinib administration.

Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose

Drug: Dasatinib+Imatinib

In this group, subjects will take imatinib prior to dasatinib administration.

Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose

Other Names:
  • Other names of Dasatinib: Sprycel
  • Other names of Imatinib: Gleevec




Primary Outcome Measures :
  1. Area under the plasma concentration versus time curve (AUC) of dasatinib [ Time Frame: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 15, and 24 hours post-dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • under healthy condition
  • Non-smokers (self-reported) age 18 -55 years
  • Body Mass Index (BMI) between 18 to 30 kg/m2 inclusive
  • Signed Informed Consent

Exclusion Criteria:

  • Any evidence of renal dysfunction (estimated creatinine clearance < 80ml/min).
  • Any evidence of impaired hepatic function (liver enzymes greater than two times the upper limit of normal or total bilirubin > 2.0 mg/dL).
  • Taking any medications other than oral contraceptives or hormonal replacement therapy.
  • Use of any known inhibitor or inducer of CYP3A or P-gp within 30 days prior to study drug administration.
  • Consumption of alcohol, grapefruit, star fruit, grapefruit products or star fruit products within the 72-hour period prior to study drug administration.
  • Women who are pregnant or currently breastfeeding.
  • Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to initial study drug administration.
  • Known adverse effect or intolerance to imatinib or dasatinib.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02129166


Sponsors and Collaborators
University of Florida
Investigators
Layout table for investigator information
Principal Investigator: Guohua An, MD, PhD University of Florida

Layout table for additonal information
Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT02129166     History of Changes
Other Study ID Numbers: IRB201400056
First Posted: May 2, 2014    Key Record Dates
Last Update Posted: October 6, 2014
Last Verified: October 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Imatinib Mesylate
Dasatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action